Does Aetna Cover Wegovy?
The verdict
Conditional on most plans
Aetna is one of the stronger commercial-coverage stories in the weight-loss GLP-1 space: its pharmacy benefit manager, CVS Caremark, made Wegovy the preferred weight-loss GLP-1 effective July 1, 2025, meaning it is covered with prior authorization on Aetna commercial plans — but Aetna's weight-loss-only PA threshold is BMI 35 or higher, stricter than the FDA label (BMI ≥30 or ≥27 with a comorbidity). For the cardiovascular indication, the lifestyle-program requirement is generally waived. Aetna Medicare Advantage excludes weight-loss use (CV indication coverable; Bridge $50/month from July 1, 2026). Employer plan carve-outs still apply.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Aetna using your member ID.
Key facts
CVS Caremark made Wegovy the preferred weight-loss GLP-1 effective July 1, 2025, benefiting Aetna commercial members — while Express Scripts (Cigna) excludes it on the base formulary. Zepbound returns as an additional CVS Caremark preferred option on October 1, 2026.
CVS Caremark / Evernorth — 2025–2026 formulary updates
Aetna's weight-loss-only PA threshold is BMI 35 or higher — stricter than the FDA label (BMI ≥30, or ≥27 with a comorbidity); the lifestyle-program requirement is generally waived for the cardiovascular indication.
Aetna — pharmacy coverage and prior authorization criteria
The Medicare GLP-1 Bridge launches July 1, 2026 at $50/month for eligible beneficiaries outside Part D, giving Aetna Medicare Advantage members a weight-loss access route the plan cannot otherwise provide.
CMS.gov — Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Aetna covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Aetna Medicare Advantage (Part D) cannot cover Wegovy for weight loss by statute. The cardiovascular risk-reduction indication — for adults with established CVD who are overweight or obese — is coverable under Aetna Medicare Advantage with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible Aetna Medicare Advantage members weight-loss access to Wegovy at $50/month outside the Part D benefit. The $50 copay does not count toward the $2,100 Part D OOP cap or TrOOP, and Extra Help cannot be applied. Bridge eligibility: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are ineligible for the Bridge. NovoCare savings card is not available to Medicare beneficiaries under federal anti-kickback rules.
Commercial / Employer
Group & marketplace plans
Aetna's pharmacy benefit is administered by CVS Caremark, which named Wegovy the preferred weight-loss GLP-1 effective July 1, 2025. This makes Aetna's commercial position notably different from Cigna (whose Express Scripts excludes Wegovy on the base formulary) and UnitedHealthcare (whose OptumRx covers only the CV indication on standard formulary). On Aetna commercial plans, Wegovy is covered with prior authorization — but the PA threshold for weight-loss-only requests is BMI 35 or higher in adults, which is meaningfully stricter than the FDA label (BMI ≥30, or ≥27 with a weight-related comorbidity). Patients with BMI 30–34 who qualify under the FDA label may be denied weight-loss-only PA at Aetna. For the cardiovascular risk-reduction indication, the lifestyle-program participation requirement is generally waived, making that PA path somewhat faster for qualifying members. ACA/individual plans are generally excluded or plan-dependent for weight-loss Wegovy. Employer plan carve-outs still apply — some self-funded employers may exclude the anti-obesity benefit even under Aetna/CVS Caremark. Commercially insured members whose Aetna plan covers Wegovy may use the NovoCare savings card to pay as little as $25/month (max $100/28-day supply). Not available to Medicare or Medicaid. CVS Caremark represents approximately 25–30 million insured individuals; Zepbound returns as an additional preferred weight-loss option on CVS Caremark effective October 1, 2026.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Where covered on Aetna commercial, approximately $25–$100/month typical cost-share (plan-specific). NovoCare savings card: commercially insured members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid. Confirm your specific tier and cost-share on the Aetna member portal.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare Advantage beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates and vary by plan tier and pharmacy. Verify actual cost-share on the Aetna member portal or with your pharmacist before starting treatment. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027. IRA-negotiated semaglutide Maximum Fair Price ($274/30-day) also takes effect January 1, 2027.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm your BMI relative to Aetna's BMI ≥35 weight-loss-only threshold
Aetna's weight-loss-only PA requires BMI 35 or higher — higher than the FDA label. If your BMI is 30–34 and you have a qualifying comorbidity, you may not qualify for weight-loss-only Wegovy coverage at Aetna, even though you meet FDA criteria. If your BMI is 35 or higher, or if you qualify for the cardiovascular indication, confirm your path with your prescriber before submitting a PA.
- 2
Use the Aetna or CVS Caremark drug-lookup tool
Visit aetna.com or the CVS Caremark member portal with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm Wegovy's preferred status, tier placement, PA requirements, and quantity limits on your specific plan. Note that employer carve-outs may override the standard preferred status — the tool will reflect your plan-specific benefit.
- 3
Work with your prescriber on prior authorization
For weight-loss-only PA: document BMI ≥35, participation in a 6-month weight-management program, and qualifying comorbidities as applicable. For the cardiovascular indication: document established CVD and overweight/obese status; the lifestyle-program requirement is generally waived. For Medicare Advantage members seeking the CV indication, confirm established CVD is in your clinical record. Track weight-loss progress for renewal — renewals typically require at least 5% documented weight loss.
Options if Aetna won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Zepbound (tirzepatide) — returning as additional CVS Caremark preferred option (10/1/2026)
Zepbound (tirzepatide, FDA-approved for weight loss) is returning as an additional preferred weight-loss option on CVS Caremark effective October 1, 2026. If Aetna's BMI ≥35 threshold for Wegovy is a barrier, ask your prescriber whether Zepbound may be an option when it returns to preferred status.
NovoCare savings card (commercially insured members)
Commercially insured Aetna members whose plan covers Wegovy can use the NovoCare savings card to pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Medicare GLP-1 Bridge (Medicare Advantage members, from July 1, 2026)
Eligible Aetna Medicare Advantage members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge starting July 1, 2026, operating outside Part D.
Compounded semaglutide
Compounded semaglutide is available without insurance or BMI requirements. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Aetna covers Wegovy as a preferred weight-loss GLP-1 on commercial plans via CVS Caremark since July 1, 2025. However, the weight-loss-only prior authorization threshold is BMI 35 or higher — stricter than the FDA label of 30. Patients with BMI 30–34 who meet FDA criteria may not qualify for weight-loss-only coverage at Aetna. For the cardiovascular indication, the lifestyle-program requirement is generally waived. Employer plan carve-outs may still exclude the benefit even under the CVS Caremark preferred formulary.
Aetna's prior authorization criteria for weight-loss-only Wegovy requests require a BMI of 35 or higher — higher than the FDA label, which approves Wegovy at BMI ≥30, or ≥27 with a weight-related comorbidity. Insurers are permitted to set their own PA thresholds above FDA-label minimums as a cost-management measure. This stricter cutoff means a patient with BMI 32 and hypertension who qualifies under the FDA label may still be denied weight-loss-only coverage at Aetna. If you have established cardiovascular disease, the CV-indication PA pathway at Aetna applies different criteria.
Aetna, Cigna, and UnitedHealthcare take three different PBM approaches. Aetna (CVS Caremark) makes Wegovy preferred on commercial plans with a stricter BMI ≥35 threshold. Cigna (Express Scripts) excludes Wegovy on the base NPF; employer opt-in plus Evernorth's $200/month cap is the route. UnitedHealthcare (OptumRx) covers only the cardiovascular indication on standard formulary, requiring opt-in for weight loss. CVS prefers, Optum CV-only, Express Scripts excludes — this three-way split defines GLP-1 coverage in 2026.
Aetna Medicare Advantage cannot cover Wegovy for weight loss by statute. It covers Wegovy for the cardiovascular risk-reduction indication with prior authorization. Starting July 1, 2026, eligible Aetna Medicare Advantage members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge, which operates outside Part D and does not count toward the $2,100 OOP cap. Members already on a Part D-covered GLP-1 are not eligible for the Bridge.
Commercially insured Aetna members whose plan covers Wegovy can use the NovoCare savings card to pay as little as $25/month (max $100 savings per 28-day supply). The card is not available to Aetna Medicare Advantage or Medicaid members under federal anti-kickback rules. If your Aetna employer plan carves out the anti-obesity benefit and Wegovy is not covered, the NovoCare self-pay program (approximately $349/month) is available regardless of coverage status.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Shield of California Cover Wegovy? | Curex
Blue Shield of CA limits new Wegovy weight-loss starts to BMI 40+ since Jan 2025. Below that threshold, weight-loss coverage is excluded. Verify your plan.
Read moreWhether or not Aetna covers Wegovy, there's a path that skips insurance
Aetna covers Wegovy as preferred on commercial plans but sets a BMI 35 or higher bar for weight-loss-only PA and excludes weight-loss use on Medicare Advantage. For patients who don't meet that threshold or want to skip the PA process, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Aetna before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.